Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a conference call and live webcast scheduled for February 7, 2023, at 8:30 AM ET to discuss its third quarter fiscal 2023 financial results and operational highlights. The call can be accessed via telephone or through an online webcast. Medicenna focuses on developing innovative immunotherapies, including its IL-2 Superkine, MDNA11, which shows promise in stimulating cancer-fighting T cells. The company’s IL-4 Empowered Superkine, MDNA55, has undergone five clinical trials and holds Fast-Track and Orphan Drug designations from the FDA.

Positive

• The upcoming conference call on February 7, 2023, may provide investors with valuable insights into fiscal 2023 results.
• MDNA11 is a novel IL-2 Superkine that preferentially stimulates cancer-fighting effector T cells.
• MDNA55, an IL-4 Empowered Superkine, has received Fast-Track and Orphan Drug statuses from the FDA.

Negative

• None.

TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights.

To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13735304. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1592653&tp_key=4301c2d5bb. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When is Medicenna's next conference call?

Medicenna's next conference call is scheduled for February 7, 2023, at 8:30 AM ET.

What will be discussed during the Medicenna conference call?

The conference call will cover Medicenna's third quarter fiscal 2023 financial results and operational highlights.

What is the ticker symbol for Medicenna Therapeutics?

The ticker symbol for Medicenna Therapeutics is MDNA, traded on both NASDAQ and TSX.